(Sept. 13, 2024) – Johnson & Johnson recently
announced that disproportionate share hospitals participating in 340B will no longer receive upfront 340B discounts on two significant drugs, Stelara and Xarelto. Beginning Oct. 15, J&J will make the 340B discount on these two drugs available through a rebate. DSH-covered entities must purchase Stelara and Xarelto through wholesalers at a commercial price. Following the administration of the drugs, they may submit rebate claim data to J&J through a new platform. Since this announcement, the Health Resources and Services Administration has
stated that the rebate model is inconsistent with the 340B statute.
--
Karen Braman